Abstract
Abstract
The grim realities of the COVID-19 pandemic have resuscitated discussions about the effectiveness of the flexibilities entrenched in the World Trade Organization Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) for improving access to medicines. This article revisits this vexed issue by examining whether a regional approach to implementing TRIPS obligations could deliver a better outcome for access, especially in low- and middle-income countries, where manufacturing capacity is almost non-existent. Using the East African Community (EAC) as a case study, the article critiques recommended implementation options under the EAC policy on TRIPS flexibilities, concluding that, if significantly implemented, these recommendations could yield a better outcome for access.
Publisher
Cambridge University Press (CUP)
Subject
General Chemical Engineering
Reference23 articles.
1. The curious case of India's Bolar provision;Rathod;Journal of Generic Medicines,2018
2. The IP waiver for COVID-19: Bad policy, bad precedent;Mercurio;International Review of Intellectual Property and Competition Law,2021
3. Access to pharmaceutical patents in the COVID-19 emergency: A case for government use in Nigeria;Adewopo;Journal of African Law,2021
4. The implications of WTO plain packaging disputes for public health measures;Mitchell;International and Comparative Law Quarterly,2021
5. Managing intellectual property rights over clinical trial data to promote access and benefit sharing in public health;Andanda;International Review of Intellectual Property and Competition Law,2013